Targeting albumin excretion rate in the treatment of the hypertensive diabetic patient with renal disease

Journal of the American Society of Nephrology

Volumn 16, Issue 3 SUPPL. 1, 2005, Pages

  Krimholtz, Michael J ^a   Karalliedde, Janaka ^a   Thomas, Stephen ^a   Bilous, Rudy ^b   Viberti, Giancarlo ^a,c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

^c GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INSULIN; LISINOPRIL; BENZIMIDAZOLE DERIVATIVE; TETRAZOLE DERIVATIVE;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE MEASUREMENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC HYPERTENSION; DISEASE COURSE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EXCRETION; FEMALE; HUMAN; KIDNEY DISEASE; MALE; MEAN ARTERIAL PRESSURE; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; ALBUMINURIA; ARTICLE; COMPARATIVE STUDY; CROSSOVER PROCEDURE; DIABETIC NEPHROPATHY; DRUG ADMINISTRATION; FOLLOW UP; HOSPITALIZATION; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FUNCTION TEST; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PROBABILITY; REFERENCE VALUE; RISK ASSESSMENT; TREATMENT OUTCOME;

ADULT; AGED; ALBUMINURIA; AMLODIPINE; BENZIMIDAZOLES; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; KIDNEY FUNCTION TESTS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PROBABILITY; REFERENCE VALUES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TETRAZOLES; TREATMENT OUTCOME;

EID: 20844451152     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2004110973     Document Type: Conference Paper

References (38)

1. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, Halle JP, Young J, Rashkow A, Joyce C, Nawaz S, Yusuf S; HOPE Study Investigators. Albuminuria and risk of cardiovascular events, death and heart failure in diabetic and nondiabetic individuals. JAMA 286: 421-426, 2001
2. Viberti GC, Hill RD, Jarrett RJ, Argyropoulos A, Mahmud U, Keen H: Microalbuminuria as a predictor clinical nephropathy in insulin dependent diabetes mellitus. Lancet 26: 1430-1432, 1982
3. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, Gans RO, Janssen WM, Grobbee DE, de Jong PE; Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group: Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in the general population. Circulation 106: 1777-1782, 2002
4. Messent JW, Elliott TG, Hill RD, Jarrett RJ, Keen H, Viberti GC: Prognostic significance of microalbuminuria in insulin dependent diabetes mellitus: A twenty-three year follow-up study. Kidney Int 41: 836-839, 1992
5. Caromori ML, Fioretto P, Mauer M: The need for early predictors of diabetic nephropathy risk. Is albumin excretion rate sufficient? Diabetes 49: 1399-1407, 2000
6. Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Warram JH, Krolewski AS: Regression of microalbumniuria in type 1 diabetes. N Engl J Med 348: 2285-2293, 2003
7. Hovind P, Tarnow L, Rossing P, Jensen BR, Graae M, Torp I, Binder C, Parving HH: Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: Inception cohort study. BMJ 328: 1105-1110, 2004
8. ACE Inhibitors in Diabetic Nephropathy Trialist Group: Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin converting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med 134: 370-379, 2001
9. Mogenson CE, Cooper M: Diabetic renal disease; from recent studies to improved clinical practice. Diabet Med 21: 4-17, 2004
10. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet 355: 253-259, 2000
11. Viberti G, Wheeldon NM; MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators: Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: A blood pressure-independent effect. Circulation 106: 672-678, 2002
12. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G Snappinn SM, Zhang Z, Shahinfar S; for the RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001
13. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; for the Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-860, 2001
14. Mogensen CE, Viberti G, Halimi S, Ritz E, Ruilope L, Jermendy G, Widimsky J, Sareli P, Taton J, Rull J, Erdogan G, De Leeuw PW, Ribeiro A, Sanchez R, Mechmeche R, Nolan J, Sirotiakova J, Hamani A, Scheen A, Hess B, Luger A, Thomas SM; Preterax in Albuminuria Regression (PREMIER) Study Group: Effect of low-dose perindopril/indapamide on albuminuria in diabetes: Preterax in albuminuria regression: PREMIER. Hypertension 41: 1063-1071, 2003
15. Jacobsen P, Andersen S, Rossing K, Hansen PV, Parving HH: Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy. Nephrol Dial Trans-plant 17: 1019-1024, 2002
16. Rossing K, Christensen PK, Jensen BR, Parving HH: Dual blockade of the renin angiotensin system in diabetic nephropathy. A randomised double blind crossover study. Diabetes Care 25: 95-100, 2002
17. Hovind P, Rossing P, Tarnow L, Smidt UM, Parving HH: Progression of diabetic nephropathy. Kidney Int 59: 702-709, 2001
18. Nussberger J, Brunner DB, Waeber B, Brunner HR. Plasma angiotensins under sustained converting enzyme inhibition with enalapril in normal humans. J Hypertens Suppl 3: S269-S270, 1985
19. Hollenberg NK, Fisher NDL, Price DA: Pathways for angiotensin II generation in intact human tissue: Evidence from comparative pharmacological intervention of the renin system. Hypertension 32: 387-392, 1998
20. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts R, Cooper M: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The Candesartan and Lisinopril Microalbuminuria (CALM) Study. BMJ 321: 1440-1444, 2000
21. Azizi M, Chatellier G, Guyene TT, Murieta-Geoffrroy D, Menard J: Additive effects of combined angiotensin converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium depleted normotensives. Circulation 92: 825-834, 1995
22. Russo D, Pisani A, Balletta MM, De Nicola L, Savino FA, Andreucci M, Minutolo R: Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis 33: 851-856, 1999
23. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T: Combination treatment of angiotensin II receptor blocker and angiotensin converting enzyme inhibitor in non diabetic renal disease (COOPERATE): A randomised controlled study. Lancet 361: 117-124, 2003
24. Argarwal R: Add-on angiotensin receptor blockade with maximized ACE inhibition. Kidney Int 59: 2282-2289, 2001
25. Willey DG, Rosenthal MA, Caldwell S: Glycated haemoglobin and plasma glycoprotein assays by affinity chromatography. Diabetologia 27: 56-58, 1984
26. Kearney EM, Mount JN, Watts GF, Slavin BM, Kind PR: Simple immunoturbidimetric method for determining urinary albumin at low concentrations using Cobas-Bio centrifugal analyser. J Clin Pathol 40: 465-468, 1987
27. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 16: 31-41, 1976
28. Campbell R, Sangalli F, Perticucci E, Cl, Aros C, Viscarra C, Perna A, Remuzzi A, Bertocchi F, Fagiani L, Remuzzi G, Ruggenenti P: Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney Int 63: 1094-1103, 2003
29. Vellusi M, Brocco E, Frigato F, Zolli M, Muollo B, Maioli M, Carraro A, Tonolo G, Fresu, Cernigoi AM, Fioretto P, Nosadini R: Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. Diabetes 45: 216-222, 1996
30. Schrier R, Estacio R, Esler A, Mehler P: Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 61: 1086-1097, 2002
31. Tarnow L, Rossing P, Jensen C, Hansen B, Paving HH. Long-term renoprotective effect of nisoldipine and lisinopril in type 1 diabetic patients with diabetic nephropathy. Diabetes Care 23: 1725-1730, 2000
32. The European Study for the Prevention of Renal Disease in Type 1 Diabetes (ESPRIT Study Group): Effects of 3 years of antihypertensive therapy on renal structure in type 1 diabetic patients with albuminuria: The European Study for the Prevention of Renal Disease in Type 1 Diabetes (ESPRIT.) Diabetes 50: 843-850, 2001
33. Melbourne Diabetic Nephropathy Study Group: Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. BMJ 16: 210-216, 1991
34. Crepaldi G, Carta Q, Deferrari G, Mangili R, Navalesi R, Santeusanio F, Spalluto A, Vanasia A, Villa G, Nodadini R: Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. The Italian Microalbuminuria Study Group in IDDM. Diabetes Care 21: 104-110, 1998
35. Bakris GL, Weir MR, DeQuattro V, McMahon FG: Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 54: 1283-1289, 1998
36. Fogari R, Preti P, Zoppi A, Rinaldi A, Corradi L, Pasotti C, Poletti L, Marasi G, Derosa G, Mugellini A, Voglini C, Lazzari P: Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients. Am J Hypertens 12: 1042-1049, 2002
37. Kuriyama S, Tomonari H, Tokudome G, Horiguchi M, Hayashi H, Kobayashi H, Ishikawa M, Hosaya T: Antiproteinuric effects of combined antihypertensive therapy in patients with overt type 2 diabetic nephropathy. Hypertens Res 25: 849-855, 2002
38. Locatelli F, Del Vecchio L, Andrulli S, Colzani S. Role of combination therapy with ACE inhibitors and calcium channel blockers in renal protection. Kidney Int 62[Suppl 82]: S53-S60, 2002